Arthritis Foundation issues first CBD guidance

  • Arthritis Foundation

  • von Liz Scherer
  • Clinical Essentials
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • The Arthritis Foundation has issued guidance for affected consumers interested in using cannabidiol (CBD)-based products for arthritis symptoms (e.g., pain, insomnia, anxiety).

Why this matters

  • CBD is not a substitute for DMARD rheumatoid arthritis (RA) treatments.
  • Advise patients interested in trying CBD to choose standardized, quality-controlled products manufactured in the United States, backed by a certificate of analyses.
  • Aside from e-cigarettes and vaping lung injuries, no major safety issues have been found with the class of CBD products overall, when taken in moderate amounts.
  • Potential drug-drug interactions may occur: corticosteroids, tofacitinib, naproxen, celecoxib, tramadol, certain selective serotonin reuptake inhibitors, fibromyalgia medications.
  • Patients experiencing adverse effects should immediately discontinue use and contact their clinician.

Key points

  • Guidance was driven by a recent survey among ~3000 patients with osteoarthritis, RA, 79% of whom reported past or current CBD use or considering trying.
  • Caution patients using liquid CBD to learn both dosing and CBD amount in each dose.
  • Sublingual CBD: start with a few milligrams twice daily; increase by the same amount after several weeks if relief is inadequate or continue use as-is if inadequate.
  • Do not add tetrahydrocannabinol to CBD product without speaking to the clinician.